Molybdenum cofactor deficiency is a devastating disease with affected patients displaying the symptoms of a combined deficiency of sulfite oxidase and xanthine dehydrogenase. Because of the extreme lability of the isolated, functional molybdenum cofactor, direct cofactor replacement therapy is not feasible, and a search for stable biosynthetic intermediates was undertaken. From studies of cocultured fibroblasts from affected individuals, two complementation groups were identified. Coculture of group A and group B cells, without heterokaryon formation, led to the appearance of active sulfite oxidase. Use of conditioned media indicated that a relatively stable, diffusible precursor produced by group B cells could be used to repair sulfite oxidase in group A recipient cells. Although the extremely low levels of precursor produced by group B cells preclude its direct characterization, studies with a heterologous, in vitro reconstitution system suggest that the precursor that accumulates in group B cells is the same as a molybdopterin precursor identified in the Neurospora crassa molybdopterin mutant nit-i, and that a converting enzyme is present in group A cells which catalyzes an activation reaction analogous to that of a converting enzyme identified in the Escherichia coli molybdopterin mutant ChiAJ.
Introduction
Molybdenum cofactor deficiency was first identified in 1978 (2) and has now been documented in more than 20 patients (3) (4) (5) . The molybdenum cofactor is a complex of a reduced pterin species termed molybdopterin and molybdenum ( Fig.   1 ). The cofactor is required for the function of at least three enzymes in humans: sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase. A deficiency of the cofactor results in symptoms of sulfite oxidase deficiency, which include seizures and other neurological abnormalities, mental retardation, and dislocated ocular lenses, in combination with xanthinuria, and most often leads to death at a young age. No symptoms attributable specifically to the absence of aldehyde oxidase have been identified. Molybdenum cofactor deficiency is inherited as an autosomal recessive trait (5) and can be diagnosed pre-natally by assay of sulfite oxidase activity in cultured amniotic cells (6) or chorionic villus biopsy (7) . However, at present there is no cure or effective therapy for molybdenum cofactor deficiency. The cofactor itself is exceedingly unstable, such that its structural characterization could be carried out only by study of stable degradation products (8, 9) . Thus direct cofactor replacement therapy is not feasible, and an understanding of the biosynthetic pathway and identification of stable precursor molecules which may be intermediates in the pathway become extremely important in development of a strategy to alleviate the symptoms of the deficiency disease.
In the results described below, we show that molybdenum cofactor deficient patients can be assigned to two complementation groups. A relatively stable diffusible molybdopterin precursor which is produced by group B cells and utilized by group A cells to synthesize active molybdenum cofactor is identified, and evidence is presented which suggests that this diffusible intermediate is identical to a molybdopterin precursor that accumulates in a molybdopterin mutant of Neurospora crassa (10) . The presence of a converting enzyme activity in group A cells that activates the precursor to yield functional molybdopterin and is analogous to a converting enzyme identified in a molybdopterin mutant of E. coli is also documented. From the results of studies described in this article, it is possible to define a pathway outlining the late steps in the biosynthesis of the molybdenum cofactor. That pathway, with the sites that appear to be defective in the two classes of molybdenum cofactor-deficient patients and in the Neurospora and Escherichia coli molybdopterin mutants indicated, is shown in Fig. 2 .
Methods
Assay of sulfite oxidase in cultured fibroblasts. Fibroblasts were obtained and cultured as described previously (1 1). For assay of sulfite oxidase activity, frozen cell pellets (3-10 X 106 cells) were thawed, suspended in 1 ml 0.01 M Tris-HCl, pH 8.5, with 50 ul of 1% sodium deoxycholate, frozen and thawed once, and passed through a 27-gauge needle several times. After the addition of 10 ul of 50 mM NaCN, the mixture was centrifuged at 12,000 g for 5 min. The supernatant fraction was applied to a column of Sephadex G-25 (PD-10, Pharmacia Fine Chemicals, Piscataway, NJ; 9.1 ml bed volume) equilibrated with 0.1 M Tris-HCl, pH 8.5, with 0.1 mM EDTA. The column was washed with 2 ml of the same buffer, and the protein fraction was eluted with 1.5 ml of buffer and assayed for sulfite oxidase activity (1 1 Culture and preparation ofcell-free extracts ofNeurospora and E. coli. Neurospora nit-i mycelia were grown, induced for nitrate reductase, and harvested as previously described (17) . Frozen mycelia were thawed, homogenized in 2 vol of 0.1 M potassium phosphate buffer, pH 7.4, with 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, and 1 mM dithiothreitol using a Duall glass grinder (Kontes Co., Vineland, NJ) and centrifuged at 15,000 g for 20 min. The supernatant fraction was used for reconstitution studies. For studies requiring further fractionation ofthe nit-i extract, 2.0 ml ofthe supernatant was applied to a column of Sephadex G-25 (PD-bI, Pharmacia Fine Chemicals) equilibrated with homogenization buffer. The column was washed with 1 ml of buffer and the excluded, high molecular weight fraction was eluted with 2.5 ml of buffer. After another 2.0-ml wash which was discarded, the low molecular weight fraction was eluted in 4 ml.
E. coli ChlAJ cells (18) were grown on LB medium (Gibco, Grand Island, NY) and harvested at late log or early stationary phase by centrifugation at 5,000 g for 25 min. Cells were washed once with water and suspended in 5 vol 0.01 M potassium phosphate, pH 7.4. Extracts were prepared with a French pressure cell and stored at -20'C.
Assay of molybdopterin precursor in conditioned culture media. Assay ofconverting enzyme infibroblast extracts. Cells were lysed as described for assay of sulfite oxidase activity. Lysates were used directly with no centrifugation or G-25 chromatography steps. Reconstitution mixtures containing 60 Ml of fibroblast extract, 30 Ml of nit-i extract (complete extract or high molecular weight fraction), and 10 M1 of0.5 M sodium molybdate were incubated at 4°C overnight and then assayed for nitrate reductase activity as described above. To demonstrate that fibroblast converting enzyme could activate the nit-i molybdopterin precursor, reconstitution mixtures were prepared as above but with 30 Ml of the nit-i low molecular weight fraction. After overnight incubation at 4°C to allow activation ofthe precursor species, 50
Ml of the nit-I high molecular weight fraction was added as a source of apo nitrate reductase to accept active molybdenum cofactor. The mixture was incubated at room temperature for 15 min to allow reconstitution and then assayed for nitrate reductase activity. APO Figure 2 . Outline of the late steps in the biosynthesis of the molybdenum cofactor in humans and microorganisms. The defects in group A patients and E. coli ChlAl are at a step preceding converting enzyme in the synthesis of molybdopterin but have not been further localized and may not be the same in each case. Compound Z is an oxidized degradation product of the molybdopterin precursor.
Assaysfor compound Z. Fibroblast extracts prepared as for assay of sulfite oxidase (uncentrifuged) and conditioned culture medium samples were acidified to pH 1 with HC1 and a solution of 1% 12 with 2% KI was added in sufficient excess to maintain a yellow color. After 30 min oxidation, samples were centrifuged at 12,000 g for 5 min and chromatographed in 50 mM ammonium acetate, pH 5, on a C-18 HPLC column (4.6 X 250 mm, 10 ,g, Alltech Associates, Deerfield, IL) using a Hewlett-Packard 1090 liquid chromatograph with an HP 1040 A diode-array detector and an HP 1046 A fluorescence detector (Hewlett-Packard Co., Palo Alto, CA). Under these conditions authentic compound Z (10) elutes at 6 min. Samples of urine (10 ml) were acidified to pH 3 with HCI, incubated for 30 min with I2JKI, centrifuged to clarify, and applied to a 0.8 ml column ofFlorisil resin (Fisher Scientific Co., Springfield, NJ) equilibrated with 0.01 N HCl. The column was washed with 10 ml of 0.01 N HCl, and the material of interest was eluted with 5 ml 50% acetone in water. The eluant was adjusted to pH 8 with NaOH and applied to a 1.0 ml column of QAE Sephadex (acetate form) equilibrated with H20. The column was washed with 3 ml of H20 followed by 10 ml 0.01 M acetic acid and the material ofinterest was eluted with 0.01 M HCI. Fractions of 3 ml were collected and analyzed for the presence ofcompound Z by HPLC in 50 mM ammonium acetate, as described above, and also with 5% methanol acidified to pH 2 with HC1 as mobile phase. Authentic compound Z, purified from E. coli ChlM cells (10) was carried through the same Florisil and QAE chromatography steps; it was eluted from a i ml column of QAE Sephadex with 0.01 N HC1 in fractions 10 and 1 1. Active molybdopterin precursor in urine samples was assayed as described for assay in conditioned cell culture medium.
Results
Reconstitution ofsulfite oxidase in culturedfibroblasts. Fibroblasts cultured from patients with molybdenum cofactor deficiency contain no active sulfite oxidase assayable by a sensitive spectrophotometric assay. However, as shown in Table I , cultures containing heterokaryons produced by polyethylene glycol fusion of cells from patient B 1 or sib B2 with those from patient Al gave positive results when assayed for sulfite oxidase. Also positive were cultures containing Al cells grown in the presence of B I or B2 cells but with no induction of heterokaryon formation. Coculture without cell fusion has been extended to include combinations of fibroblasts from a large number of molybdenum cofactor-deficient patients and the results are summarized in Table II . Initially it was found that all crosses that contained cells from B1 or B2 showed reconstitution of sulfite oxidase activity while crosses between any of the other patients gave negative results. These results define two complementation groups: group A consisting of seven patients (A 1.-A7) and group B consisting of B I and B2. Recently, another unrelated molybdenum cofactor-deficient patient has been assigned to group B. As shown in Table II , cells from patient B3 complement A6 and A7 but yield no activity when cultured with cells from B 1. The presence of sulfite oxidase activity in cocultured fibroblasts in the absence of heterokaryon formation suggests that complementation is occurring by means of a diffusible molecule produced and excreted into the culture medium by one cell class which is then taken up and processed to produce active molybdenum cofactor by cells of the other classification group. To establish that such is the case, to determine which complementation group produces and which uses the putative precursor species, and to gain some insight into the stability of such a precursor species, experiments were undertaken culturing recipient cells in medium which had been conditioned by molybdopterin. It would appear as well that the genetic defect in group A lies in an enzyme that precedes the enzyme which is defective in group B in the molybdopterin biosynthetic pathway.
Characterization of the molybdopterin precursor produced by group B patients. Because of the exceedingly low levels of molybdoenzymes, molybdopterin, and its precursors which are present in cultured fibroblasts, it was clear that purification of the diffusible intermediate from group B cells or conditioned medium would be a difficult task, further hampered by the lengthy assay procedure relying on reconstitution of sulfite oxidase activity in cultured group A cells. To overcome these problems and facilitate a partial characterization of the precursor produced by group B patients, we turned to a heterologous in vitro reconstitution system which is described below:
The most widely used assay for active molybdenum cofactor utilizes the nit-i mutant of Neurospora crassa, which is defective in molybdopterin biosynthesis. The nit-i strain accumulates a soluble, inactive apo nitrate reductase which can be readily reconstituted in vitro by a source ofactive molybdenum cofactor. The reconstitution takes place rapidly at room temperature or somewhat more slowly at 4VC requiring only a crude extract of nit-i mycelia, a source of molybdenum cofactor or molybdopterin and inorganic molybdate. After reconstitution, the active nitrate reductase is incubated with substrates and nitrite produced is quantitated by a calorimetric procedure.
One precaution must be taken when utilizing the nit-i system as an assay for active molybdopterin. While the nit-i mutant contains no functional molybdopterin, it does accumulate a low molecular weight precursor of molybdopterin (10). In the presence of an appropriate converting enzyme, added exogenously to the nit-i extracts, this precursor can be activated to molybdopterin which in turn will reconstitute the apo nitrate reductase. The converting enzyme which activates the nit-i precursor was first identified (10) in a mutant of E. coli, ChlAi, which also is defective in molybdopterin synthesis. Specifically, it was observed that incubation of an extract of ChlAI cells with an unfractionated extract of nit-i led to the appearance of active nitrate reductase. Separation of the low molecular weight fractions of the nit-i by gel exclusion chromatography produced a preparation of apo nitrate reductase (high molecular weight fraction) which was activated by ChlAI only when the nit-i precursor (low molecular weight fraction) was added back. Thus it is possible to differentiate between nit-i nitrate reductase reconstitution which occurs as a result of the addition of active molybdopterin and that which results from addition of a source of converting enzyme which activates the nit-i precursor by the fact that the former requires only the high molecular weight fraction of the nit-i extract while the latter requires both high and low molecular weight fractions. Recently we have shown that the nit-i assay can be applied as a sensitive measure of active molybdopterin in fibroblast extracts (13) ; in such studies it was prudent to use extracts of nit-i from which all low molecular weight precursors had been removed.
Neither the low molecular weight molybdopterin precursor which accumulates in nit-i nor the converting enzyme which is present in ChlAI has been fully characterized, although studies to this end are currently in progress. Nevertheless, enough information is already available to allow us to ask whether these late steps in the pathway of cofactor biosynthesis/activation observed in microorganisms are present in humans as well. That is, is the diffusible precursor that accumulates in group B patients related to the molybdopterin precursor in Neurospora nit-i? And, is there an activity in fibroblasts from group A patients that is equivalent to the converting enzyme found in E. coli ChI4i?
Early experiments were directed at the first question. Conditioned medium from group B cells was incubated with ChlAI extracts and then added to extracts of nit-I (high molecular weight fraction) and assayed for nitrate reductase reconstitution. No activity was observed, but from the negative result it was not possible to conclude whether the group B precursor differs from the nit-i precursor and thus was not recognized and activated by ChlAI converting factor or whether levels of precursor were merely too low to detect. (10) directed at characterizing the molybdopterin precursor in Neurospora nit-i suggested that an unusual fluorescent pterin species that could be isolated after acidic iodine oxidation of nit-i extracts might be an inactive oxidized degradation product of the molybdopterin precursor. More recently, we have shown this to be true by the demonstration that the purified active precursor is oxidized to this same fluorescent species (termed compound Z; Johnson et al., manuscript in preparation). Thus, an attempt was made to show the presence of compound Z in samples from group B patients. Neither conditioned medium nor fibroblasts from group B patients, when treated with acidic iodine, yielded significant levels of compound Z. However, as shown in Fig. 3 , a urine sample from patient Bl did indeed contain compound Z. The peak of material eluting at the same position as authentic compound Z, detected by its absorption at 300 nm, was fluorescent and, as shown in Fig. 3 , had an absorption spectrum essentially identical to that of the standard material. Significantly, no peak corresponding to compound Z was identified in chromatograms of urine from patient Al or from a control individual. A second aliquot of the same urine sample from patient B1 was processed in the same manner but with the iodine oxidation step omitted. The yield of compound Z was identical suggesting that conversion of active precursor to compound Z occurred either before excretion or in the aged sample which had been stored for 5 yr and subjected to many freeze-thaw cycles. A stored sample of urine from patient B2 yielded the same results: a level of compound Z comparable to that in the B I sample which did not vary with the inclusion or omission of the iodine oxidation step. Fresh urine samples from patients B1 and B2 were not available for study; however, a fresh sample from patient B3 was obtained and assayed for compound Z. Levels ofcompound Z were very low (15% of that seen in B 1) in the sample analyzed without iodine oxidation, but equivalent to B 1 after iodine oxidation.
The iodine-dependent appearance of compound Z in the sample from patient B3 suggested that it might be possible to detect the presence of the parent functional molybdopterin precursor in a sample which had not been iodine-oxidized. As shown in Table V ', I 1.5 yielded no compound Z even with iodine oxidation, and the stored sample of urine from patient B 1, which yielded its full complement of compound Z without iodine oxidation, both were incapable of reconstituting significant levels of nitrate reductase activity. A preliminary investigation of the stability of the precursor activity in the urine sample from patient B3 has revealed that activity was not greatly diminished by a number of freeze-thaw cycles but was totally abolished by iodine oxidation.
Discussion
The presence of converting enzyme in fibroblasts from group A patients and active precursor and compound Z in urine from group B patients is strong evidence that the late steps in the synthesis of molybdopterin in man and microorganisms are identical. The final steps in the pathway of molybdopterin biosynthesis have been summarized in Fig. 1 . According to this scheme, the molecular defect in group B patients and in the Neurospora nit-i mutant may be assigned to a gene which codes for or regulates the expression of converting enzyme. As a consequence of this defect, the molybdopterin precursor, which is the substrate for the converting enzyme, and/or its oxidized product accumulate and can be identified in culture media from group B cells, in Neurospora nit-i cells (10) and culture medium (Johnson et al., manuscript in preparation), and in urine samples from group B patients. The absence of detectable levels of compound Z in control urine samples would suggest that under normal circumstances levels of the molybdopterin precursor are quite low; appearance ofprecursor in extracellular fluids and culture media may result only when intracellular levels are raised due to absence of functional converting enzyme.
The processing of the molybdopterin precursor to yield molybdopterin is carried out by a converting enzyme in group A fibroblasts and ChlAJ cells. These results suggest that the molecular defect in group A patients and in ChIAJ is earlier in the biosynthetic pathway (prior to the converting enzyme), but do not establish whether the ChLiA and group A mutations are at the same step or in fact whether all group A patients have the same molecular defect. If any or all ofthe group A patients lack an enzyme which directly precedes converting enzyme on the biosynthetic pathway, they may accumulate the substrate of that defective enzyme. Analysis of urine samples from group A patients for the presence of unusual pterin species which may be related to molybdopterin and the molybdopterin precursor could prove very useful in future studies of molybdopterin biosynthesis in humans.
The converting enzymes in fibroblasts and ChLAJ which are assayed by their activation of the nit-i molybdopterin precursor would appear to have been designed to carry out the same catalytic reaction. Further studies will be required to determine whether the reaction mechanisms are indeed identical and to ascertain the molecular form and cellular localization of the enzymes in these widely divergent life forms.
From the results presented above, it appears very likely that the diffusible precursor produced by group B cells is identical to the molybdopterin precursor present in Neurospora nit-l. The implications of such a conclusion are far-reaching.
The precursor in Neurospora nit-i and certain other E. coli molybdopterin mutants is present in extremely high amounts and it, as well as its oxidized product, compound Z, is amenable to purification and structural characterization (Johnson et al., manuscript in preparation). Such information should prove invaluable in terms of understanding how the labile molybdopterin is synthesized and its fragile side chain components protected prior to activation and may ultimately prove to be of therapeutic value to molybdenum cofactor-deficient patients. If further studies verify that the purified molybdopterin precursor isolated from nit-i is able to reconstitute sulfite oxidase when added to the culture medium of group A cells, the possibility of employing the precursor species in vivo to correct molybdenum cofactor deficiency may indeed become quite real.
